Serotonin receptor 2C (HTR2C) and schizophrenia: Examination of possible medication and genetic influences on expression levels

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 134 B, Issue 1, 2005, Pages 84-89

  Castensson, Anja ^a   Åberg, Karolina ^a   McCarthy, Shane ^b   Saetre, Peter ^a   Andersson, Björn ^b   Jazin, Elena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

mRNA expression; Neuroleptic drugs; Promoter polymorphisms; Psychiatric disease; Serotonia receptor 2C

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; COMPLEMENTARY DNA; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; PROMAZINE; RISPERIDONE; SEROTONIN 2C RECEPTOR; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; GENOTYPE; HAPLOTYPE; HTR2C GENE; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOPHARMACOTHERAPY; RECEPTOR GENE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIPSYCHOTIC AGENTS; BASE SEQUENCE; FRONTAL LOBE; GENE EXPRESSION REGULATION; GENOTYPE; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RECEPTOR, SEROTONIN, 5-HT2C; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 15744393382     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30151     Document Type: Article

References (37)

1. Barnes NM, Sharp T. 1999. A review of central 5-HT receptors and their function. Neuropharmacology 38(8):1083-1152.
2. Buckland PR, D'Souza U, Maher NA, McGuffin P. 1997. The effects of antipsychotic drugs on the mRNA levels of serotonin 5HT2A and 5HT2C receptors. Brain Res Mol Brain Res 48(1):45-52.
3. Castensson A, Emilsson L, Preece P, Jazin EE. 2000. High-resolution quantification of specific mRNA levels in human brain autopsies and biopsies. Genome Res 10(8):1219-1229.
4. Castensson A, Emilsson L, Sundberg R, Jazin E. 2003. Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis. Biol Psychiatry 54(11):1212-1221.
5. Deutch AY, Duman RS. 1996. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization. Neuroscience 70(2):377-389.
6. Deutch AY, Ongur D, Duman RS. 1995. Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: A novel locus of antipsychotic drug action. Neuroscience 66(2):337-346.
7. Di Matteo V, De Blasi A, Di Giulio C, Esposito E. 2001. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 22(5):229-232.
8. Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V. 2003. RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem 87(6):1402-1412.
9. Dudbridge F. 2003. Pedigree disequilibrium tests for multilocus haplotypes Genet Epidemiol 25(2):115-121.
10. Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran DP, Jonak GJ, Hartig PR. 1999. Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 21(Suppl 2):82S-90S.
11. Heid CA, Stevens J, Livak KJ, Williams PM. 1996. Real time quantitative PCR. Genome Res 6(10):986-994.
12. Herrick-Davis K, Grinde E, Teitler M. 2000. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine 2C receptors. J Pharmacol Exp Ther 295(1):226-232.
13. Howell WM, Jobs M, Gyllensten U, Brookes AJ. 1999. Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms. Nat Biotechnol 17(1):87-88.
14. Ichikawa J, Dai J, Meltzer HY. 2001. DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res 907(1-2):151-155.
15. Kapur S, Remington G. 2001. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517.
16. Kuroki T, Kawahara T, Yonezawa Y, Tashiro N. 1999. Effects of the serotonin2A/2C receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 23(7):1259-1275.
17. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. 1998. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44(11):1099-1117.
18. Meltzer HY. 1999. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(Suppl 2):106S-115S.
19. Mottagui-Tabar S, McCarthy S, Reinemund J, Andersson B, Wahlestedt C, Heilig M. 2004. Analysis of 5-hydroxytryptamine 2c receptor gene promoter variants as alcohol-dependence risk factors. Alcohol Alcohol 39(5):380-385.
20. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. 1999. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274(14):9472-9478.
21. Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E. 2001. RNA editing of the human serotonin 5-HT2C receptor. Alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 24(5):478-491.
22. Rauser L, Savage JE, Meltzer HY, Roth BL. 2001. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299(1):83-89.
23. Reynolds GP, Zhang ZJ, Zhang XB. 2002. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359(9323):2086-2087.
24. Seeman P. 2002. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 47(1):27-38.
25. Segman RH, Ebstein RP, Heresco-Levy U, Gorfine M, Avnon M, Gur E, Nemanov L, Lerer B. 1997. Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene. Psychiatr Genet 7(2):75-78.
26. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, et al. 2000. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 152(4):408-413.
27. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW. 1995. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7(1):169-172.
28. Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ. 2001. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 6(4):373-379.
29. Stephens M, Donnelly P. 2003. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73(6):1162-1169.
30. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978-989.
31. Sundberg R, Castensson A, Jazin E. 2005. Statistical methodology in case-control 5′-nuclease assays: Statistical design, modeling and inference for identification of differentially expressed genes. Submitted.
32. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. 1995. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374(6522):542-546.
33. Tremblay PO, Gervais J, Rouillard C. 1998. Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists. Eur J Neurosci 10(11):3546-3555.
34. Xie E, Zhu L, Zhao L, Chang LS. 1996. The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant. Genomics 35(3):551-561.
35. Youngren KD, Moghaddam B, Bunney BS, Roth RH. 1994. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett 165(1-2):41-44.
36. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. 2000. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 43(3):373-376.
37. Zhang ZJ, Zhang XB, Sha WW, Reynolds GP. 2002. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7(7):670-671.